Today we announced that our company will acquire Acer Therapeutics Inc., effectively expanding our rare disease portfolio and accelerating our growth into a commercial company. The acquisition brings us unique rare disease commercial capabilities that will support our existing pipeline as it advances. We are encouraged by the strength of Acer’s portfolio of rare programs and are excited to foster our shared goal of bringing life changing therapeutics to patients with significant unmet needs. Join our conference call today, 8/31 at 8:30 a.m. ET to learn the details of the acquisition: https://bit.ly/47MqzQk Read the full announcement here: https://bit.ly/44FZTOE #WeAreZevra
Zevra Therapeutics
Pharmaceutical Manufacturing
Celebration, FL 8,887 followers
A Rare Approach to Therapeutics
About us
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.
- Website
-
http://www.zevra.com
External link for Zevra Therapeutics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Celebration, FL
- Type
- Public Company
- Founded
- 2006
Locations
-
Primary
1180 Celebration Boulevard
Celebration, FL 34747, US
-
2500 Crosspark Road
Coralville, IA 52241, US
-
2200 Kraft Drive
Blacksburg , VA 24060, US
-
1001 Pennsylvania Ave, NE
13th Floor North
Waashington, DC 20004, US
Employees at Zevra Therapeutics
Updates
-
Our Sr. Director, U.S. Medical Affairs and Patient Advocacy, Tara Greene, is presenting at the NATIONAL NIEMANN-PICK DISEASE FOUNDATION Family Support and Medical Conference in Salt Lake City, Utah. Don’t miss Tara's "Corporate Update," this Saturday, July 13, at 11:00 a.m. MT. #NNPDF
-
-
Zevra Therapeutics is attending #SERGG 2024 conference, July 11-13. Our medical team will present a poster highlighting real-world outcomes from our expanded access program of arimoclomol, in adults with #NPC. More about the meeting: https://bit.ly/3zvHGcB
-
-
Zevra Therapeutics today announced that the FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee to review the New Drug Application for #arimoclomol as an orally delivered, first-in-class treatment for Niemann-Pick Disease Type C (#NPC) on August 2, 2024. More details at https://bit.ly/3S155sV
-
-
Happy 4th of July from the Zevra team! 🎆 We wish everyone a joyful and relaxing holiday filled with great moments with friends and family. #StarsAndStripes #IndependenceDay
-
-
Zevra Therapeutics announced the appointment of Rahsaan Thompson as Chief Legal Officer, Secretary and Compliance Officer and Alison Peters as Chief People Officer. Mr. Thompson brings more than 25 years of experience as a business leader and attorney in the biotech industry and Ms. Peters brings more than 25 years of experience in human capital management developing high performing teams and leaders in the biotech industry. Learn more at https://bit.ly/3RPZw08
-
-
Zevra looks forward to attending the NATIONAL NIEMANN-PICK DISEASE FOUNDATION's Family Support and Medical Conference next week! At this annual event for the #NPC and #ASMD communities, our team will lead a Family Working Group session to gain insights from families affected by NPC on important topics facing the #raredisease community. #NNPDF
-
-
Zevra Therapeutics reposted this
Hypersomnia Foundation is proud to celebrate 10 years of building a community that educates, empowers, and supports people who fight sleepiness. Here is Hypersomnia Foundation's board member, Veronica Moore, reflecting on HF's ten years of service. Thank you for being on this journey with us. We are grateful to the sleep community, which continues to fiercely advocate for those with hypersomnia disorders. It is our honor to advocate alongside you. #ThisIsIH #forthesleepyones #hypersomniaawareness #idiopathichypersomnia #sleepdisorder #FakeAwake
-
-
Zevra Therapeutics reposted this
📢 Spread the word! Project Sleep cordially invites Members of Congress, staffers and interested stakeholders to attend "Awakening America: A Congressional Briefing on Sleep and Public Health" on Tuesday, July 16th, 2024 from 12:00pm - 12:45pm (Eastern) in the Rayburn House Office Building, Room 2075 in Washington, DC. ➡️ This event will cover new resources and tools now available to constituents nationwide. This briefing will also discuss gaps in early detection and diagnosis for the one in five Americans living with sleep disorders, along with legislative recommendations and updates on federal programs. ✨ Speakers Include: Dr. Michael Grandner, University of Arizona Dr. Kali Cyrus, Patient Advocate Julie Flygare, JD, President & CEO, Project Sleep 🏛️ Following the briefing, Project Sleep will invite Capitol staff to participate in a free educational sleep screening event to discuss concerns about their own sleep or wakefulness. Spread the word, learn more and RSVP: https://lnkd.in/gSQ8MvVw
-
-
Patient Worthy’s Jessica Lynn met with Daniel Gallo, PhD, our Senior Vice President of Medical Affairs and Advocacy, to discuss our first-in-class investigational therapeutic, #arimoclomol, and the unmet needs of the #NPC community. As the Prescription Drug User Fee Act action date for arimoclomol approaches in September, Gallo provides insights into how Zevra has remained patient-centric in our push to advance effective treatment. Full article can be found at https://bit.ly/3RJckFs
-